Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Netanja Slager
Introduction
Netanja Slager is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of ophthalmology through his innovative research and development of therapeutic compounds. His work focuses on addressing critical issues related to retinal health and gene expression.
Latest Patents
Netanja Slager holds a patent for a double-stranded oligonucleotide compound aimed at down-regulating the expression of the CASP2 gene. This invention relates to compositions and methods for inhibiting the loss of retinal ganglion cells in subjects. The patent describes a method of non-invasively applying an ophthalmic composition that contains a therapeutically effective amount of siRNA. This siRNA targets genes associated with the loss of retinal ganglion cells, thereby providing a potential therapeutic approach to preserving vision.
Career Highlights
Netanja Slager is associated with Quark Pharmaceuticals, Inc., where he continues to advance his research in gene therapy and ophthalmic treatments. His work has garnered attention for its potential to improve outcomes for patients suffering from retinal diseases.
Collaborations
He collaborates with notable colleagues, including Elena Feinstein and Evgenia Alpert, who contribute to the innovative research environment at Quark Pharmaceuticals.
Conclusion
Netanja Slager's contributions to the field of ophthalmology through his patented inventions highlight the importance of innovation in medical science. His work not only addresses critical health issues but also paves the way for future advancements in retinal therapies.